Here’s what you should know:
1. Immuron conducted its last clinical visit on Oct. 9, and its final close-out visit on Oct. 18, following 28 weeks of study and observation.
2. Immuron studied a total of 133 nonalcoholic fatty liver disease patients.
3. The company expects to report top-line results once the data is finalized and reviewed by its Scientific Advisory Board.
4. The company disclosed interim results of 122 patients in July 2017. In these patients IMM-124E caused a statistically significant reduction in the ALT enzyme over time when compared to a placebo.
Immuron CEO Jerry Kanellos said in a release, “The completion of these patient studies marks a pivotal inflection point for Immuron, as we now look forward to analysing and reporting the data results.”
More articles on gastroenterology:
Exact Sciences’ revenue jumps by 158% in Q3 — 5 insights
DIY bowel prep leaves GI physicians concerned — 7 insights
Enhanced disinfection makes no difference for duodenoscope contamination
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.